EcoDrugPlus

Potassium Intermediate/small Conductance Calcium-Activated Channel, Subfamily N, Member 4

Ensembl ID : ENSIPUG00000002629
Gene Symbol: KCNN4
3 Cross references
187 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSIPUG00000005009
Gene Symbol: KCNJ11
1 Cross references
188 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSIPUG00000004221
Gene Symbol: KCNJ2A
4 Cross references
207 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3a

Ensembl ID : ENSIPUG00000021360
Gene Symbol: KCNJ3A
3 Cross references
225 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3b

Ensembl ID : ENSIPUG00000013622
Gene Symbol: KCNJ3B
3 Cross references
17 Possible Orthologues:

Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1a

Ensembl ID : ENSIPUG00000004383
Gene Symbol: KCNMA1A
3 Cross references
235 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSIPUG00000011481
Gene Symbol: KCNA5
4 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSIPUG00000005214
Gene Symbol: KCND3
4 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2

Ensembl ID : ENSIPUG00000024496
Gene Symbol: LOC108271553
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSIPUG00000013189
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSIPUG00000003814
Gene Symbol: KCNQ2A
2 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 5a

Ensembl ID : ENSIPUG00000024247
Gene Symbol: KCNQ5A
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).